Latest news for EVT (OTC:EVHEF) Stock

EVT is an Australian-based provider of entertainment, hospitality, and leisure-related services. The entertainment arm consists of cinema operations in Australia (Event Cinemas), New Zealand, and Germany, as well as the State Theatre in Sydney, complemented by various restaurants and bars. The ventures arm consists of development of the group's vast property portfolio and provision of hotel management solutions to third parties. The travel arm consists of the group's hotel operations (QT, Rydges, Atura), and the Thredbo ski and mountain-biking resort. The group generates the most of its earnings in Australia.

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Westlake Securities analyst Casey Ryan maintains Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and raises the price target from $2.65 to $4.67.

News

Price Target

Analyst Ratings

VRAR

Westlake Securities Maintains Buy on Glimpse Group, Raises Price Target to $4.67

TSLA: -6% &#x7C; <a href="https://www.benzinga.com//node/42613402">NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025</a>
&nbsp;
NKE: -6% &#x7C; <a href="https://www.benzinga.com//node/42605414">Nike Q2 Earnings: Revenue Beat, EPS Beat, Shares Jump, and then reverse — 'Nike Being Nike Again'</a>
&nbsp;
HUMA: 91% &#x7C; <a href="https://www.benzinga.com//node/42609617">FDA Approves Humacyte's SYMVESS For Treating Extremity Vascular Injuries</a>

Movers

Trading Ideas

HUMA

TSLA

Market-Moving News for December 20th

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42607141/tryngolza-olezarsen-approved-in-u-s-as-first-ever-treatment-for-adults-living-with-familial-chylom" rel="noreferrer noopener">lead to acute pancreatitis (AP)</a>.
SHTG is&nbsp;a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level.&nbsp;
Tryngolza is the first-ever&nbsp;FDA-approved treatment that significantly and substantially reduces&nbsp;triglyceride levels in adults with FCS and provides a clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).
Tryngolza is self-administered via an auto-injector once-monthly.
The FDA approval was based on Phase 3 Balance trial data in adult patients.
In the Balance study, Tryngolza 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084).&nbsp;
Reductions from baseline to 12 months were further improved, with Tryngolza achieving a placebo-adjusted 57% mean triglyceride reduction.&nbsp;
Tryngolza also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the Tryngolza group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group.&nbsp;
Tryngolza will be available in the U.S. before year end.
Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2, and ESSENCE – for SHTG. Olezarsen has not been reviewed or approved for SHTG.
In November, Ionis Pharmaceuticals announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome (AS). The trial is expected to start in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769886/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome" rel="noreferrer noopener">the first half of 2025</a>.
AS typically presents in infancy and is characterized by profound intellectual disability, impaired verbal abilities, and severe motor impairment.
Price Action: At last check on Friday, IONS stock was up 3.79% at $36.94 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600482/mercks-investigational-two-drug-regime-for-hiv-meets-primary-goal-in-two-late-stage-trials" target="_blank" rel="noreferrer noopener">Merck&#8217;s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials</a></li>
</ul>

Biotech

Health Care

General

IONS

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

JP Morgan analyst Michael Mueller upgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Neutral to Overweight and raises the price target from $122 to $125.

Upgrades

JP Morgan Upgrades Federal Realty Investment to Overweight, Raises Price Target to $125

Further information regarding the final result of the offer, including the number of shares tendered, will be disclosed in JBT's upcoming 8-K filing.

JBT Says Voluntary Takeover Offer For Marel hf. Expired; Has Now Satisfied All Conditions To Offer, Including Minimum Acceptance Condition

JP Morgan analyst Anthony Paolone upgrades Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) from Neutral to Overweight and raises the price target from $45 to $49.

JP Morgan Upgrades Kilroy Realty to Overweight, Raises Price Target to $49

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with a Buy and maintains $45 price target.

Reiteration

ORKA

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target

Mizuho analyst David Bellinger maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Neutral and raises the price target from $72 to $80.

Mizuho Maintains Neutral on CarMax, Raises Price Target to $80

JP Morgan analyst Anthony Paolone downgrades Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) from Overweight to Neutral and announces $26 price target.

Downgrades

JP Morgan Downgrades Kimco Realty to Neutral, Announces $26 Price Target

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $60 price target.

Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

TAOP

Taoping Announced That It Received Notification From The Nasdaq Stock Market Confirming The Company Has Been Granted An Additional 180 Calendar Day Period For Compliance Under Its Minimum Bid Price Requirement Through June 16, 2025

JP Morgan analyst Michael Mueller downgrades Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Overweight to Neutral and announces $19 price target.

JP Morgan Downgrades Healthcare Realty Trust to Neutral, Announces $19 Price Target

JP Morgan analyst Michael Mueller downgrades Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Overweight to Neutral and lowers the price target from $78 to $75.

LINE

JP Morgan Downgrades Lineage to Neutral, Lowers Price Target to $75

HC Wainwright &amp; Co. analyst Arthur He maintains LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) with a Buy and lowers the price target from $6 to $2.

LVTX

HC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $2

Contracts

AECOM Says Awarded Several New Positions On Additional AMP8 UK Water Infrastructure Frameworks

SBC Medical Group Holdings Says Its Unit SBC Medical Group Co. Has Decided To Sell All Shares Of Its Subsidiaries, SBC Kijimadaira Resort Co And Skynet Academy Co

XCharge said it is committed to sound corporate governance and transparent communication with its shareholders. The Company's operations continue as normal, and its financial condition remains strong.
 &nbsp;

XCHG Says It Is Not Aware Of Any Material News Or Events That Would Account For Unusual Trading Activity

<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">December 17, 2024 NHTSA CAMPAIGN NUMBER: 24V935000</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">TPMS Light May Not Remain Illuminated/FMVSS 138</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Software Update Repairs Recall</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Driving with improperly inflated tires increases the risk of a crash.</a>
NHTSA Campaign Number:&nbsp;24V935000
Manufacturer&nbsp;Tesla, Inc.
Components&nbsp;TIRES
Potential Number of Units Affected&nbsp;694,304
Summary
Tesla, Inc. (Tesla) is recalling certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles. The tire pressure monitoring system (TPMS) warning light may not remain illuminated between drive cycles, failing to warn the driver of low tire pressure. As such, these vehicles fail to comply with the requirements of Federal Motor Vehicle Safety Standard number 138, "Tire Pressure Monitoring Systems."
Remedy
Tesla released an over-the-air (OTA) software update, free of charge. Owner notification letters are expected to be mailed February 15, 2025. Owners may contact Tesla customer service at 1-877-798-3752. Tesla's number for this recall is SB-24-00-018.
Notes
Owners may also contact the National Highway Traffic Safety Administration Vehicle Safety Hotline at 1-888-327-4236 (TTY 1-800-424-9153), or go to <a href="http://www.nhtsa.gov" title="www.nhtsa.gov">www.nhtsa.gov</a>.

NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) chief Hock Tan expressed enormous conviction over the sustainability of the <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence frenzy</a> as Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and TikTok parent ByteDance splurged on designing custom processors that accelerate training and deployment of AI systems, the Financial Times reports.
Reportedly, OpenAI and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) also tapped Broadcom to develop their AI server chips to diversify their exposure to Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Broadcom stock has surged over 101% year-to-date.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561430/match-group-analyst-flags-tinder-woes-industry-challenges-for-stock-downgrade" rel="noreferrer noopener">Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade</a>
Tan <a target="_blank" href="https://www.ft.com/content/5b4160b7-6920-4bf2-a1a8-f1404b513d8f" rel="noreferrer noopener">told</a> FT that he expected the demand to continue for at least ten years, citing their enormous return potential.
Tan stressed to the FT that clients were intensely ramping up AI infrastructure investment plans spanning three to five years.
He does not expect the phenomenon to lose steam until his clients run out of finances.
Last week, Tan told investors Broadcom <a target="_blank" href="https://www.benzinga.com//node/42488220" rel="noreferrer noopener">could generate</a> tens of billions of dollars in additional annual revenue from AI chips by 2027.
Tan&#8217;s experience and dealmaking prowess fuelled speculation of rescuing struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). However, Tan claimed no hostile offers since 2018, when it was tracking Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), which succumbed to regulatory opposition.
Tan backed his thesis by citing investments by OpenAI and Elon Musk&#8217;s xAI in data centers in 2024.
Tan told the FT that its customers will build clusters of up to 1 million AI chips by 2027. However, Tan said that even 1 million chips may not suffice the AI ambitions of OpenAI and Anthropic.
Broadcom&#8217;s stock price rallied 24% in a single day last Friday after its AI revenues had surged by 220% in fiscal 2024. The chipmaker added over $200 billion to its market cap, breaching the $1 trillion milestone for the first time.
Rosenblatt&#8217;s Hans Mosesmann&nbsp;expects <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42489281/broadcoms-ai-chip-leadership-puts-pressure-on-nvidia-and-marvell-analysts-say" rel="noreferrer noopener">Broadcom&#8217;s growing moat</a> in expanding custom-chip (ASIC) AI and surging AI opportunities to intensify the rivalry with Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia. B of A Securities&#8216; Vivek Arya&nbsp;credited Broadcom with maintaining a position at customer Apple.
Investors can gain exposure to Broadcom through Amplify ETF Trust Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>) and First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Action:&nbsp;AVGO stock closed lower by 2.37% at $218.32 Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AAPL

AVGO

GOOG

GOOGL

HACK

INTC

NVDA

QCOM

TDIV

Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions

HC Wainwright &amp; Co. analyst Yi Chen reiterates Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) with a Buy and maintains $3 price target.

Comments

EVT

News

Latest news for EVT (OTC:EVHEF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga